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between ANX≥8/DEP≥8 rates during/after RT vs BSL. The 
impact of ICIQ/IPSS scores, as well as that of BSL ANX/DEP, 
on the risk of ANX≥8/ DEP≥8 at 6-12 months was tested in a 
logistic regression model.  
Results: The rates of ANX≥8 did not differ from BSL at any 
time, though an increase was found at 3-6 months (6 months 
vs BSL: 23.3% vs 14.8%, p=0.12). On the contrary, DEP≥8 was 
significantly higher during and after RT (6 months vs BSL: 
22.2% vs 8.8%, p=0.02; difference at 12 months not 
statistically significant). No impact on ANX≥8/DEP≥8 of RT 
intent, fractionation, AAD or RT technique emerged at any 
time. 
ANX≥8 at 6-12 months was predicted by 2-variable models 
including BSL ANX and ICIQ scores at corresponding times or, 
alternatively, at RT end, with high discriminative power (AUC 
ranging between 0.86 and 0.90). The same variables also 
predicted DEP≥8 at 6 months (AUC=0.88). A further analysis 
showed that the changes in ANX≥8/DEP≥8 over time are 
highly modulated by ICIQ score (Figure1). 
 
Conclusions: Incontinence, during and after PoP WPRT, and 
baseline ANX/DEP are major factors in increasing the risk of 
clinically significant anxiety/depression. End RT ICIQ score is 
a good predictor of increased risk of ANX/DEP at 6-12 
months. 
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Clinical decision is a complex moment and, as stated by Sir 
W.Osler, ‘Medicine is a science of uncertainty and an art of 
probability’. 
Medical doctors foster their ‘internal databases of 
knowledge’ by daily clinical practice, but time-by-time their 
performances question their capacity to storage and to 
communicate data, as well as to act efficiently.  
The rapid learning technology is nowadays supporting the 
transfer of this process to ‘external databases of knowledge’, 
with the aim to have less individual variability in the 
understanding of the knowledge and more reliability in the 
prediction of the outcomes.  
By rapid-learning technology data routinely generated 
through patient care and clinical research feed into an ever-
growing databank or set of coordinated databases. The 
health care system “learns” by routinely and iteratively 
collecting data in a planned and strategic manner, generating 
evidence through retrospective analysis of existing data as 
well as data from prospective studies and generating new 
hypotheses for investigation.  
Even if many issues in term of data definition, accuracy and 
interoperability are still to be solved this approach is not 
mandatory: it is unavoidable!  
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Big multi-institutional medical databases will be technically 
feasible in near future. The validity of such databases 
critically depends on uniform coding and comprehensive 
registration of all clinical relevant information including 
toxicity and long term follow up. Provided all technical 
problems and data protection issues could be solved, the 
question arises what kind of conclusion could be drawn from 
these databases for clinical oncology. Databases will give in 
realistic overview how cancer patients are treated in specific 
situations including the presumably high variability of the 
applied treatments. Clinical outcome data including toxicity 
and survival would give an impression, what can be achieved 
with currently available treatments. The widespread use of 
these databases will likely result in some potentially 
unbeneficial changes in clinical practice and a number of 
risks, if statistical analysis is preformed and causal 
interpretations is pursued. The universal availability of 
clinical outcomes in a big database will led to smaller 
variations of actually applied treatments, since presumably 
favorable treatments would be identified in these databases, 
and physician would prefer to prescribe, what most other 
physician prescribe in the same situation. These presumably 
favorable treatments were likely influenced by a number of 
biases resulting from preconceptions of the oncological 
community. Innovative treatments initiated by single 
investigators or institutes that don’t follow the 
preconceptions of the majority of the oncological community 
maybe hampered, if mainstream treatments derived from big 
databases are easily accessible for home physicians and 
patients. The risk that knowledge form big databases in 
absence of evidence from randomized trials results in self-
fulfilling prophecies is high. One important risk of 
misinterpretation results from the fact that clinical databases 
do typically not allow to perform an intent to treat analysis. 
Since complete documentation of all potentially criteria 
involved in treatment decisions cannot be comprehensively 
documented in a clinical database, the risk of 
misinterpretation is high. Propensity scores have been 
proposes to correct for these biases, but are unable to 
correct for unknown relationships. Whenever causal 
interpretations are derived from big clinical databases, one 
needs to be aware that interpretation requires a high degree 
of caution. Results from clinical big databases should be 
regarded as hypothesis generating and cannot at all be 
considered as substitute for randomized clinical trials. 
Forcing physicians, who have no intrinsic motivation, to 
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participate to databases will certainly decrease the average 
quality of the data and consequently aggravate the risks. 
Therefore, participation to databases should not be made 
mandatory.  
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Rational: Radiation oncology is very sensitive to quality 
assurances due to its specificity: different tumours, various 
patients, multiple sequences of treatment with high tech 
machines and information systems. Obtaining the best results 
as possible does imply a quality control of the equipment 
(machines…), of the professionals (certification), of the 
organisations (audits, accreditation) and finally of the 
treatment itself (clinical validation). The key point is to have 
indicators able to give a robust evaluation on quality 
parameters. 
Material and methods: A quality policy is based on 3 steps: 
description of Standard operation procedures (SOP’s), 
consideration of Human factors (Radiotherapy Resource 
Management) and implementation of “feed back “committee. 
Developing indicators for every step is critical to evaluate in 
time and compare QA policies. However, the most 
challenging step remains the evaluation of treatment 
outcome itself. 
Results: Quality of care is mostly depending on individuals 
but on the contrary, indicators must be independent of 
human appreciation and valid for all organizations and 
processes. Side to the classical ones (accidents, incidents, 
near misses...), treatment results must be taken into 
consideration. Prospective data base mining  as well as 
patients related outcomes (PRO’s), independent of the care 
professionals, may be the most valuable indicators to be 
considered in the near future. 
Conclusion : Quality is critical in “good medical practice”. 
The evaluation of results (audits, publications...) remains the 
gold standard and will be mostly patient dependent in the 
near future. 
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Synopsis: The ASTRO Accreditation Program for Excellence 
(APEx™) provides the opportunity to build upon and integrate 
ASTRO’s quality improvement initiatives. Findings from APEx 
will potentially highlight variances in the delivery of radiation 
oncology care, inform educational offerings, and identify 
topics for clinical practice statements and quality measures 
development. APEx was created to encourage accountability 
in radiation therapy practices. The program establishes 
standards of performance derived from white papers and 
consensus practice guidance for radiation oncology. Facilities 
that obtain practice accreditation will have the systems, 
personnel, and policies and procedures that are needed to 
meet the APEx standards for high-quality, safe patient care. 
 The mission of the APEx is to recognize facilities by 
objectively assessing the radiation oncology care team, 
policies and procedures, and the facility. APEx provides an 
objective review by professional peers of essential functions 
and processes of radiation oncology practices. It offers 
transparent, measurable, evidence- and consensus-based 
standards that emphasize a professional commitment to 
safety and quality. Radiation oncology practices accredited 
by ASTRO will: 
• Undergo an objective, external review of radiation 
oncology programs, policies and processes; 
• Demonstrate respect for protecting the rights of patients 
and responsiveness to patient needs and concerns; and 
• Adopt cutting edge procedures to encourage safety and 
quality of care. 
  
The standards reflect competencies and practices identified 
and endorsed in the publication, Safety is No Accident: A 
Framework for Quality Radiation Oncology and Care. This 
framework provides guidance for essential practices in 
radiation oncology. It describes a multidisciplinary approach 
to care that focuses on quality measurement to encourage 
safe, effective and peer-reviewed radiation oncology care. 
The ASTRO standards translate the goals outlined by the 
Framework into objective, verifiable expectations for 
performance in radiation oncology practice. ASTRO will work 
closely with radiation oncologists, interdisciplinary radiation 
therapy professionals, consumers and payers to identify 
improved performance indicators and measures of 
accountability. Through this continuous quality improvement, 
the APEx program and its accredited facilities will be on the 
forefront of accountability and performance. 
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During the last decades, the evolution of radiotherapy has 
been associated with a remarkable development of high 
technology treatment equipment, advanced imaging 
techniques, and sophisticated treatment planning systems. As 
a consequence of the high complexity of today’s 
radiotherapy, extensive efforts are spent on quality controls 
in order to guarantee accurate and safe treatments. 
However, the aim of modern quality management is to go 
beyond compliance, and to continuously improve the quality 
of the treatments. In this situation, it is highly desirable to 
consider alternative options and to search for ways to use 
limited time and resources more efficiently. 
The purpose of the present ESTRO task group on quality 
management is therefore to review methods used in 
industrial processes, and to survey the current use of such 
tools in radiotherapy. For this purpose, questionnaires have 
been sent out to clinical radiotherapy and medical physics 
departments throughout Europe in order to collect 
information regarding present quality management practice. 
